ECDC is creating new infrastructure to allow for regular monitoring and analysis of COVID-19 vaccine effectiveness (VE) over time, using a multi-country approach, through the implementation of studies in different settings.
The risk assessed in this update is as follows: based on current levels of vaccination coverage and the dominance of the Delta variant in the EU/EEA, what risk does SARS-CoV-2 pose to the general population and the vulnerable population in the coming months?
EU/EEA countries that have not yet achieved high enough COVID-19 vaccination coverage in their total populations, which are planning to relax non-pharmaceutical interventions during the next two weeks, run a high risk of experiencing a significant surge of cases, hospitalisations and mortality from now until the end of November.
Based on current evidence, there is no urgent need for the administration of booster doses of vaccines to fully vaccinated individuals in the general population, according to a technical report issued by the European Centre for Disease Prevention and Control (ECDC).
The SARS-COV-2 Delta variant of concern is spreading quickly across Europe and has now become the dominant strain across much of the region, according to new data.
This document provides a review of evidence on three topics of interest (effectiveness of partial vaccination, immunogenicity and effectiveness of vaccination for previously infected individuals and safety and immunogenicity of heterologous schedules) to inform ongoing decision-making in relation to national vaccination policies and strategies in the European Union and European Economic Area (EU/EEA) countries.
In order to promote an exchange of emerging good practices and lessons learned regarding equitable uptake of COVID-19 vaccination in EU/EEA countries, ECDC held a webinar on 23 June 2021 to bring together stakeholders from national public health authorities and from civil society.